Drug Search Results
More Filters [+]

CR-1447

Alternative Names: cr-1447, cr1447, cr 1447
Latest Update: 2023-06-27
Latest Update Note: Clinical Trial Update

Product Description

CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in preclinical studies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28814476/)

Mechanisms of Action: AR Agonist

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Swiss Group for Clinical Cancer Research
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CR-1447

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer|Adenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SAKK 21/12

P2

Terminated

Breast Cancer|Adenocarcinoma

2018-08-02

Recent News Events

Date

Type

Title